-
平臺編號：bio-69134
-
國際編號：CRL-5807?
-
細胞信息： NCI-H358
-
規(guī)格：Frozen
-
用途：ATCC原裝細胞
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
NCI-H358
生長狀態(tài)：貼壁生長
組織來源：bronchiole; alveolus
ATCC Number：CRL-5807?
相關疾病：其他疾病
細胞形態(tài)：上皮樣
運輸方式：凍存運輸
是否是腫瘤細胞：1
物種來源：人
器官來源：肺
數(shù)量：大量
規(guī)格：0.1ml Designations: NCI-H358 [H-358, H358]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: lung
Tissue: bronchiole; alveolus
Disease: bronchioalveolar carcinoma; non-small cell lung cancer
Cellular Products:lung surfactant associated protein A (SP-A)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
Isolation: Isolation date: 1981
Tumorigenic:Yes
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 8,12
D16S539: 12,13
D5S818: 10,12
D7S820: 10,11
THO1: 6
TPOX: 8,9
vWA: 17
GenoType: EGFR (wt) [90471 ]
Gender: male
Comments:This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates in 1981 from tumor tissue obtained from a patient prior to initiation of chemotherapy.
Ultrastructural studies demonstrated the presence of cytoplasmic structures characteristic of Clara cells.
The cells expressed protein and RNA of SP-A, the major lung surfactant associated protein.
SP-B and SP-C RNA was not expressed.
They have a reported colony forming efficiency of 0.83% in soft agarose.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Remove medium, and rinse with 0.25% trypsin, 0.53 mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Doubling Time: 38 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
purified DNA:ATCC CRL-5807D
References: 22434: Brower M, et al. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46: 798-806, 1986. PubMed: 3940644
23081: Gazdar AF, et al. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 50: 5481-5487, 1990. PubMed: 2386953
23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
90471: Sordella R, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004. PubMed: 15284455
組織來源：bronchiole; alveolus
ATCC Number：CRL-5807?
相關疾病：其他疾病
細胞形態(tài)：上皮樣
運輸方式：凍存運輸
是否是腫瘤細胞：1
物種來源：人
器官來源：肺
數(shù)量：大量
規(guī)格：0.1ml Designations: NCI-H358 [H-358, H358]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: lung
Tissue: bronchiole; alveolus
Disease: bronchioalveolar carcinoma; non-small cell lung cancer
Cellular Products:lung surfactant associated protein A (SP-A)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
Isolation: Isolation date: 1981
Tumorigenic:Yes
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 8,12
D16S539: 12,13
D5S818: 10,12
D7S820: 10,11
THO1: 6
TPOX: 8,9
vWA: 17
GenoType: EGFR (wt) [90471 ]
Gender: male
Comments:This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates in 1981 from tumor tissue obtained from a patient prior to initiation of chemotherapy.
Ultrastructural studies demonstrated the presence of cytoplasmic structures characteristic of Clara cells.
The cells expressed protein and RNA of SP-A, the major lung surfactant associated protein.
SP-B and SP-C RNA was not expressed.
They have a reported colony forming efficiency of 0.83% in soft agarose.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Remove medium, and rinse with 0.25% trypsin, 0.53 mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Doubling Time: 38 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
purified DNA:ATCC CRL-5807D
References: 22434: Brower M, et al. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46: 798-806, 1986. PubMed: 3940644
23081: Gazdar AF, et al. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 50: 5481-5487, 1990. PubMed: 2386953
23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
90471: Sordella R, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004. PubMed: 15284455
